Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VARIVAX PE34 given with M-M-R II in toddlers
2017-001910-27Phase 3
- Sponsor
- Merck & Co.
- Start
- Jul 2019
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varicella virus vaccine live and M-M-R II in chickenpox (2 arms), sponsored by Merck & Co. Primary endpoint: Varicella zoster virus antibody response rate.
02
Drugs
varicella virus vaccine liveM-M-R II
03
Conditions
chickenpox
Beyond the preview
Go deeper on 2017-001910-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001910-27.